Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2022. Gross royalty revenues of $65.6 million from Glaxo Group Limited (“GSK”) for the third quarter...

Click to view original post